BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel FL. PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. Seminars in Nuclear Medicine 2015;45:268-81. [DOI: 10.1053/j.semnuclmed.2015.03.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Novruzov E, Mori Y, Antke C, Dabir M, Schmitt D, Kratochwil C, Koerber SA, Haberkorn U, Giesel FL. A Role of Non-FDG Tracers in Lung Cancer? Semin Nucl Med 2022:S0001-2998(22)00054-X. [PMID: 35803770 DOI: 10.1053/j.semnuclmed.2022.05.004] [Reference Citation Analysis]
2 Chai R, Wang Q, Qin P, Zeng J, Ren J, Zhang R, Chu L, Zhang X, Guan Y. Differentiating Central Lung Tumors from Atelectasis with Contrast-Enhanced CT-Based Radiomics Features. Biomed Res Int 2021;2021:5522452. [PMID: 34820455 DOI: 10.1155/2021/5522452] [Reference Citation Analysis]
3 Li Y, Lin X, Li Y, Lv J, Hou P, Liu S, Chen P, Wang M, Zhou C, Wang X. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study. Mol Imaging Biol 2021. [PMID: 34816283 DOI: 10.1007/s11307-021-01679-w] [Reference Citation Analysis]
4 Borrelli P, Ly J, Kaboteh R, Ulén J, Enqvist O, Trägårdh E, Edenbrandt L. AI-based detection of lung lesions in [18F]FDG PET-CT from lung cancer patients. EJNMMI Phys 2021;8:32. [PMID: 33768311 DOI: 10.1186/s40658-021-00376-5] [Reference Citation Analysis]
5 Martin O, Schaarschmidt BM, Kirchner J, Suntharalingam S, Grueneisen J, Demircioglu A, Heusch P, Quick HH, Forsting M, Antoch G, Herrmann K, Umutlu L. PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations. J Nucl Med 2020;61:1131-6. [DOI: 10.2967/jnumed.119.233940] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
6 Giesel FL, Heussel CP, Lindner T, Röhrich M, Rathke H, Kauczor H, Debus J, Haberkorn U, Kratochwil C. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur J Nucl Med Mol Imaging 2019;46:1754-5. [DOI: 10.1007/s00259-019-04346-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
7 Li Y, Wan YY, Zhu B. Immune Cell Metabolism in Tumor Microenvironment. Adv Exp Med Biol 2017;1011:163-96. [PMID: 28875490 DOI: 10.1007/978-94-024-1170-6_5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
8 Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med 2019;60:801-5. [PMID: 30954939 DOI: 10.2967/jnumed.119.227967] [Cited by in Crossref: 225] [Cited by in F6Publishing: 195] [Article Influence: 75.0] [Reference Citation Analysis]
9 Raptis CA, Ludwig DR, Hammer MM, Luna A, Broncano J, Henry TS, Bhalla S, Ackman JB. Building blocks for thoracic MRI: Challenges, sequences, and protocol design. J Magn Reson Imaging 2019;50:682-701. [PMID: 30779459 DOI: 10.1002/jmri.26677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Flechsig P, Lindner T, Loktev A, Roesch S, Mier W, Sauter M, Meister M, Herold-mende C, Haberkorn U, Altmann A. PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide. Mol Imaging Biol 2019;21:973-83. [DOI: 10.1007/s11307-018-1296-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
11 Flechsig P, Rastgoo R, Kratochwil C, Martin O, Holland-Letz T, Harms A, Kauczor HU, Haberkorn U, Giesel FL. Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis. Mol Imaging Biol 2018;20:1044-52. [PMID: 29679299 DOI: 10.1007/s11307-018-1196-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, Iagaru AH, Mcconathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME. ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. J Nucl Med 2017;58:1174-6. [DOI: 10.2967/jnumed.117.193524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Carreras-delgado J, Pérez-dueñas V, Riola-parada C, García-cañamaque L. PET/MRI: A luxury or a necessity? Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2016;35:313-20. [DOI: 10.1016/j.remnie.2016.07.002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Carreras-Delgado JL, Pérez-Dueñas V, Riola-Parada C, García-Cañamaque L. PET/MRI: A luxury or a necessity? Rev Esp Med Nucl Imagen Mol 2016;35:313-20. [PMID: 27349326 DOI: 10.1016/j.remn.2016.05.007] [Reference Citation Analysis]
15 Shen G, Hu S, Liu B, Kuang A. Diagnostic Performance of Whole-Body PET/MRI for Detecting Malignancies in Cancer Patients: A Meta-Analysis. PLoS One 2016;11:e0154497. [PMID: 27124545 DOI: 10.1371/journal.pone.0154497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]